Nemes Rush Group LLC Acquires 7,114 Shares of Johnson & Johnson (NYSE:JNJ)

Nemes Rush Group LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 14.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 55,954 shares of the company's stock after purchasing an additional 7,114 shares during the quarter. Nemes Rush Group LLC's holdings in Johnson & Johnson were worth $8,092,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of JNJ. Norges Bank bought a new position in shares of Johnson & Johnson during the 4th quarter worth about $4,390,037,000. Raymond James Financial Inc. bought a new position in Johnson & Johnson during the fourth quarter worth about $1,339,878,000. Janus Henderson Group PLC grew its stake in shares of Johnson & Johnson by 228.1% in the 3rd quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company's stock valued at $549,223,000 after purchasing an additional 2,356,359 shares during the period. Vanguard Group Inc. lifted its position in shares of Johnson & Johnson by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock worth $33,666,460,000 after buying an additional 1,772,706 shares during the period. Finally, Franklin Resources Inc. boosted its stake in Johnson & Johnson by 11.4% in the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company's stock valued at $2,721,355,000 after buying an additional 1,729,281 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Activity

In related news, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Remove Ads

Johnson & Johnson Stock Down 7.6 %

Shares of JNJ stock traded down $12.60 on Tuesday, hitting $153.25. 23,293,291 shares of the stock were exchanged, compared to its average volume of 7,720,065. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $369.30 billion, a P/E ratio of 23.04, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The business has a 50-day moving average of $159.16 and a 200 day moving average of $155.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the firm posted $2.29 EPS. The business's revenue was up 5.3% on a year-over-year basis. Equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.24%. Johnson & Johnson's dividend payout ratio (DPR) is presently 74.59%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on JNJ shares. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research note on Monday, March 10th. Argus raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Barclays increased their target price on Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a report on Tuesday, January 28th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 19th. Finally, Morgan Stanley decreased their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and an average price target of $171.33.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.